In A01, C. Reinhardt and T. Wunderlich will generate a versatile in vivo platform based on existing autochthonous mouse models of SCLC, to address fundamental questions in SCLC biology and treatment response. Especially the hypothesis that SCLCs display enhanced sensitivity against cell cycle checkpoint-abrogating therapeutic interventions will be analyzed. Moreover, the team will perform in vivo insertional mutagenesis screens to search for mediators of resistance against chemo- and chemo-immunetherapy.
Professor for Clinical and Molecular Oncology (W2) and attending physician (Oberarzt)
University Hospital of Cologne
Department I for Internal Medicine
Junior Research Group Leader
Max Planck Institute for Metabolism Research